NCT02306577

STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)

STRIBILD in Non-Nucleoside Resistant Patients, An Evaluation of Safety and Efficacy in Vulnerable Population (SINNR STUDY)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Vancouver Infectious Diseases Centre · Academic / Other
• Sex: All
• Age: 19 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The SINNR study will evaluate the virologic efficacy (viral load \<50 copies/mL)and safety of STRIBILD administered for 48 weeks to HIV-infected current or recent illicit drug users.

Detailed description

The SINNR study is a pilot, observational, open label study. It will evaluate the virologic efficacy (viral load \<50 copies/mL), safety, and immunologic response of STRIBILD administered for 48 weeks to HIV-infected current or recent illicit drug users. Approximately 30 HIV-infected current or recent illicit drug users (≥19y.o.,\<70y.o.) from Vancouver Infectious Diseases Centre and Regina General Hospital, University of Saskatchewan will be taking an oral 1 STRIBILD tablet once a day for 48 weeks. Additionally, adherence to STRIBILD over 48 weeks and quality of life will be measured in this population.

Conditions

• HIV
• Illicit Drug User

Interventions

Type	Name	Description
DRUG	STRIBILD	Taking oral 1 STRIBILD tablet once a day for 48 weeks

Timeline

• Start date: 2014-11-01
• Primary completion: 2016-04-01
• Completion: 2016-07-01
• First posted: 2014-12-03
• Last updated: 2015-06-03

Locations

1 site across 1 country: Canada